ICD-10 Code M04.2: Cryopyrin-associated periodic syndromes

Key Takeaways

ICD-10 Code M04.2 (Cryopyrin-Associated Periodic Syndromes) is a billable, specific ICD-10-CM diagnosis code valid for FY 2026 reimbursement.

M04.2 covers three distinct CAPS subtypes: Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and NOMID/CINCA.

Never assign M04 (parent code) when M04.2 applies; always use the most specific child code available per ICD-10-CM coding guidelines.

Pabau’s claims management software supports accurate diagnostic code entry and documentation workflows for rare autoinflammatory conditions.

Rare autoinflammatory disorders are among the most challenging diagnostic codes to document correctly. Most practices see only a handful of CAPS patients per year, which means coding errors go undetected until a denial lands on the desk. ICD-10 Code M04.2 covers a well-defined group of conditions, and getting it right from intake to claim submission saves significant rework for rheumatology and immunology teams.

This reference guide covers the code definition, included CAPS subtypes, code hierarchy, differentiation from adjacent M04 codes, documentation requirements, and billing considerations for practices submitting claims under M04.2. Rheumatologists, immunologists, and coders working in integrative medicine and specialist clinic settings will find the key practical details here.

ICD-10 Code M04.2: Definition and Clinical Description

ICD-10 Code M04.2 is the billable diagnosis code for Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare inherited autoinflammatory disorders caused by gain-of-function mutations in the NLRP3 gene. The NLRP3 gene encodes the cryopyrin protein, a critical component of the inflammasome complex. When this complex is overactivated, it triggers excessive interleukin-1 beta (IL-1β) production and leads to systemic inflammation.

Beyond the genetic cause, CAPS affects multiple organ systems simultaneously. Patients typically present with recurrent fever episodes, urticarial rash, musculoskeletal pain, conjunctivitis, and fatigue. The severity spectrum ranges from mild cold-triggered episodes to life-threatening neonatal-onset multiorgan disease.

Structurally, the code sits within the M04 Autoinflammatory Syndromes block, itself part of the broader M00-M99 Diseases of the Musculoskeletal System and Connective Tissue chapter. As classified by the WHO ICD-10 international classification, M04.2 falls under the autoinflammatory syndromes range, with the clinical modification applied in the United States tracked through ICD-10-CM maintained by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS).

In practice, M04.2 became effective for FY 2026 on October 1, 2025, continuing unchanged from prior fiscal years. Medicare, Medicaid, and commercial payers accept it for reimbursement.

Code Hierarchy and Structure for M04.2

Understanding where M04.2 sits within the broader ICD-10-CM hierarchy prevents the most common coding error: using the parent M04 code when a specific child code applies.

Additionally, the parent code M04 carries a note that it should not be used when a more specific child code applies. Any claim submitted with M04 alone, rather than M04.2, M04.1, M04.8, or M04.9, will likely face a medical necessity or specificity rejection from payers who require the most specific code available. Coders familiar with autistic disorder diagnostic coding will recognize the same hierarchy principle at work here.

The M04 block also carries a Type 2 Excludes note for Crohn’s disease (K50). A Type 2 Excludes means both conditions can coexist and clinicians may use both codes simultaneously on a claim when appropriate.

Included Conditions Under ICD-10 Code M04.2

M04.2 is the single ICD-10-CM code that covers three distinct CAPS subtypes. Each represents a different severity tier of the same underlying NLRP3 gene mutation spectrum.

Familial Cold Autoinflammatory Syndrome (FCAS)

FCAS is the mildest CAPS subtype. Symptoms are triggered by generalized cold exposure rather than localized contact. Patients develop urticarial rash, fever, arthralgia, and conjunctivitis within hours of cold exposure. FCAS was historically termed “familial cold urticaria,” and the official tabular list includes that synonym under M04.2.

Muckle-Wells Syndrome (MWS)

By contrast, MWS represents the intermediate severity tier. In addition to recurrent fever and urticarial rash, patients develop progressive sensorineural hearing loss and are at significant risk for AA amyloidosis affecting the kidneys. Episodes are not reliably cold-triggered, which distinguishes MWS clinically from FCAS.

NOMID and CINCA Syndrome

At the most severe end of the spectrum, Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Chronic Infantile Neurological, Cutaneous, and Articular (CINCA) syndrome represent the same condition under two names. NOMID is the American designation; CINCA is the European equivalent. This is the most severe CAPS subtype, presenting at birth with persistent urticarial rash, central nervous system inflammation (chronic aseptic meningitis), and destructive arthropathy. ICD-10-CM coding conventions explicitly place both NOMID and CINCA under M04.2.

• FCAS (Familial Cold Autoinflammatory Syndrome): Mildest form, cold-triggered, includes “familial cold urticaria” synonym
• Muckle-Wells Syndrome (MWS): Intermediate severity, progressive hearing loss, AA amyloidosis risk
• NOMID/CINCA: Most severe, neonatal onset, CNS and joint involvement, both names map to M04.2

How M04.2 Differs from M04.1 and M04.9

Misassigning codes within the M04 block is the primary coding risk for autoinflammatory syndrome encounters. The clinical distinctions between codes are meaningful, and payers with medical necessity edits will flag mismatches between the diagnosis and the documented clinical picture.

M04.1 vs. M04.2

M04.1 covers Periodic Fever Syndromes, a group of autoinflammatory conditions defined by episodic rather than persistent fever. These include TRAPS (tumor necrosis factor receptor-associated periodic syndrome), Familial Mediterranean Fever, and Hyper-IgD syndrome (mevalonate kinase deficiency). PFAPA falls under M04.8, not M04.1. The key distinction: PFAPA and TRAPS do not involve NLRP3 mutations and do not affect cryopyrin regulation. If a patient has FCAS or MWS, M04.2 is correct; if the patient has PFAPA or TRAPS, M04.1 applies.

Practices managing rare immunological conditions alongside situational anxiety ICD-10 classification in the same patient record should note that comorbid mental health diagnoses can be coded simultaneously without exclusion conflicts for M04.2.

M04.9 vs. M04.2

M04.9 (Autoinflammatory Syndrome, Unspecified) is the fallback code for patients where clinical workup has not yet identified the specific syndrome type. Once diagnostic criteria or genetic testing results support CAPS classification, the coder must move to M04.2. Retaining M04.9 after the clinician confirms a CAPS diagnosis is a coding error that may delay prior authorization for IL-1 inhibitor biologics, since payers often require the specific subtype code to process specialty drug authorizations.

Accurate coding starts with accurate records

Pabau helps rheumatology and immunology practices capture diagnosis codes, manage clinical notes, and submit clean claims – all from one platform. See how our claims management software reduces denials for complex specialty codes.

Book a demo

Documentation Requirements for M04.2

Insufficient documentation is the leading cause of claim denials and audit exposure for rare disease codes. For ICD-10 Code M04.2, the clinical record must support both the diagnosis and the specific CAPS subtype being coded. This is especially important when IL-1 inhibitor biologics are prescribed, as payers require detailed prior authorization documentation tied to the diagnosis code.

Required clinical elements

• Diagnosis statement: An explicit diagnosis of CAPS, FCAS, Muckle-Wells Syndrome, or NOMID/CINCA documented by the treating clinician
• Symptom history: Documented pattern of recurrent fever episodes, urticarial rash, and at least one of: arthralgia, conjunctivitis, hearing loss, or CNS involvement
• Genetic or clinical confirmation: NLRP3 mutation testing result, or clinical criteria met per specialist assessment, documented in the chart
• Treatment context: If the clinician prescribes IL-1 inhibitors (rilonacept, canakinumab, or anakinra), the record must connect the CAPS diagnosis to the treatment indication
• Subtype specification: Document which CAPS subtype applies (FCAS, MWS, or NOMID/CINCA) to justify M04.2 over M04.9

Practices using digital intake forms can build autoinflammatory symptom history templates directly into the patient onboarding workflow, capturing the episodic fever pattern, cold-trigger history, and family history fields that coders need for clean M04.2 claims.

Furthermore, detailed documentation also protects against retrospective audits. Rare disease codes like M04.2 draw scrutiny precisely because they are uncommon and carry high-cost biologic associations. A thorough clinical record stored in structured patient records creates an auditable evidence trail linking the diagnosis to the treatment plan and the submitted code.

For practices managing complex ICD-10 documentation across multiple specialties, including documentation challenges like those seen with intraparenchymal hemorrhage ICD-10 documentation, the principle is consistent: specificity in the clinical note drives specificity in the code.

Billing and Claims Guidance for M04.2

Medicare, Medicaid, and commercial payers recognise M04.2 as a valid diagnosis code. It is used as a primary or secondary diagnosis code depending on the encounter context. Several billing considerations are specific to CAPS coding.

Using M04.2 as primary vs. secondary diagnosis

Specifically, when the patient presents for management of their CAPS condition, M04.2 is the principal diagnosis. When the visit primarily addresses a complication (such as sensorineural hearing loss or renal amyloidosis in MWS), the complication code leads and the coder lists M04.2 as a secondary code to explain the underlying cause.

Combination coding with Crohn’s disease

The Type 2 Excludes note on the M04 parent block for Crohn’s disease (K50) means both codes can be submitted together when a patient carries both diagnoses. This is a useful distinction for gastroenterology-immunology co-management patients. Neither code excludes the other; both may appear on the same claim.

Prior authorization for IL-1 inhibitors

Canakinumab (Ilaris), rilonacept (Arcalyst), and anakinra (Kineret) are the primary biologic agents used in CAPS management. Payers require prior authorization for these drugs, and the authorization request must include the M04.2 code along with clinical documentation supporting the CAPS diagnosis and subtype. Submitting M04.9 instead of M04.2 on a prior authorization request for a CAPS-indicated biologic commonly triggers an initial authorization denial.

The CDC/NCHS ICD-10-CM coding tool provides the official tabular list entry for M04.2, including applicable includes notes and any coding instructions that apply to the current fiscal year. Cross-referencing this tool before submitting claims confirms that no additional notes or use-additional-code instructions have been added in the current FY update cycle.

Practices can also verify M04.2 coding rules and crosswalk data through the AAPC Codify ICD-10-CM lookup, which provides synonym lists, includes notes, and related code references in a searchable format. Using claims management software that integrates diagnostic code validation reduces the risk of these errors reaching payer submission.

For practices building out their rare disease coding workflows, automated billing workflows can flag encounters with autoinflammatory diagnosis codes for secondary review before claim submission, catching subtype specificity issues before they become denials. Practices in functional medicine treating complex inflammatory presentations may encounter M04.2 less frequently but benefit equally from structured code validation workflows.

For a broader view of how patient care management workflows support accurate coding across complex diagnoses, and how EHR integration reduces manual code entry errors, both are relevant reads for practices managing rare inflammatory conditions.

Conclusion

CAPS coding errors tend to cluster at one decision point: using M04.9 (unspecified) instead of M04.2 once a CAPS subtype has been confirmed. Closing that gap requires structured documentation at the clinical level and a validation step before claim submission.

Pabau’s claims management software supports diagnostic code workflows for specialty practices, including documentation templates, structured patient records, and pre-submission validation. To see how Pabau handles complex diagnostic coding for rheumatology and immunology teams, book a demo.

Continue your research

Need a structured framework for clinical documentation in specialty care? Safer clinical notes covers the documentation principles that protect against audit exposure across complex diagnoses.

Managing compliance requirements for a specialist clinic? HIPAA compliance for clinic software outlines how practice management platforms support secure, audit-ready records.

Exploring how practice software handles billing workflows? Practice management platforms that integrate diagnostic coding with claims submission reduce manual rework for specialty practices.

Frequently Asked Questions